natgillin/translations-raw huggingface dataset:
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.
ispitivanju ishoda u bolesnika s postojećom teškom makrovaskularnom bolešću, incidencija ozbiljnog zatajenja srca bila je 1,6% viša uz pioglitazon nego uz placebo kad se pioglitazon dodao terapiji koja je uključivala inzulin.
The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily.
Uobičajena početna doza je jedna tableta od 15 mg ili od 30 mg pioglitazona jedanput na dan.
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat.
Stvaranje i prisutnost kamenaca u mokraćnom sustavu s posljedičnom nadraženošću i hiperplazijom postavila se kao temeljni mehanizam opaženog tumorogenog odgovora u mužjaka štakora.
If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible.
Ako se tijekom terapije pioglitazonom razine ALT povise na vrijednosti koje su 3 puta iznad gornje granice normale, razine jetrenih enzima treba čim prije ponovno provjeriti.
Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.
Farmakokinetika stanja dinamičke ravnoteže u bolesnika u dobi od 65 ili više godina slična je onoj u mlađih osoba.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
U jednom ispitivanju u trajanju od 20 tjedana, osim što je smanjio trigliceride natašte, pioglitazon je smanjio postprandijalnu hipertrigliceridemiju tako što je utjecao kako na apsorbirane trigliceride, tako i na one sintetizirane u jetri.
In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg.
Dodavanje pioglitazona metforminu u kombiniranim ispitivanjima rezultiralo je prosječnim povećanjem tjelesne težine tijekom jedne godine za 1,5 kg, a dodavanje pioglitazona sulfonilureji za 2,8 kg.
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
- metforminom i sulfonilurejom, u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) s nedostatnom kontrolom glikemije usprkos dvojnoj peroralnoj terapiji.
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss,
- ako imate dijabetičku ketoacidozu (komplikacija šećerne bolesti koja uzrokuje nagli gubitak na tjelesnoj težini, mučninu i povraćanje).
Skin and subcutaneous tissue disorders sweating uncommon
Poremećaji kože i potkožnog tkiva znojenje manje često
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL cholesterol levels, compared with placebo, metformin or gliclazide.
U kliničkim ispitivanjima u trajanju do dvije godine, pioglitazon je snizio ukupne trigliceride u plazmi i slobodne masne kiseline te povisio razine HDL-kolesterola u usporedbi s placebom, metforminom i gliklazidom.
In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention.
Kliničkim ispitivanjima pioglitazona pokazalo se da je povećanje tjelesne težine povezano s dozom, što može biti posljedica nakupljanja masnog tkiva, a u nekim je slučajevima povezano sa zadržavanjem tekućine.
Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity.
Slične promjene u raspodjeli masnog tkiva u tijelu uz pioglitazon praćene su poboljšanom inzulinskom osjetljivošću.
Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus.
Poboljšava se kontrola glikemije natašte i nakon obroka u bolesnika sa šećernom bolešću tipa 2.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.
Pokazalo se da liječenje pioglitazonom smanjuje proizvodnju glukoze u jetri i povećava periferno uklanjanje glukoze u slučaju inzulinske rezistencije.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator.
Prijelomi su opaženi u 2,6% žena koje su uzimale pioglitazon u odnosu na 1,7% žena liječenih usporednim lijekom.
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations.
Poboljšana kontrola glikemije povezana je sa smanjenjem koncentracije inzulina u plazmi kako natašte, tako i nakon obroka.
3 In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
3 U kontroliranim kliničkim ispitivanjima, incidencija prijavljenih zatajenja srca uz liječenje pioglitazonom bila je podjednaka onoj u skupinama koje su primale placebo, metformin ili sulfonilureju, ali povišena kad se pioglitazon primjenjivao u kombiniranoj terapiji s inzulinom.
In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year.
U ispitivanju kombinirane terapije u trajanju od dvije godine u kojem se pioglitazon uspoređivao s gliklazidom kad se dodavao metforminu, kontrola glikemije mjerena kao prosječna promjena u odnosu na početnu vrijednost HbA1c bila je slična u obje terapijske skupine nakon jedne godine.
The dose may be increased in increments up to 45 mg once daily.
Doza se može postupno povećavati do 45 mg jedanput na dan.
Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays.
Pioglitazon nije pokazao genotoksično djelovanje u sveobuhvatnom nizu testova genotoksičnosti in vivo i in vitro.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg u odnosu na placebo) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa
- if you have cysts on your ovaries (polycystic ovary syndrome).
- ako imate ciste na jajnicima (sindrom policističnih jajnika).
7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
7 U kliničkim ispitivanjima pioglitazona, incidencija povišenja ALT-a za više od tri puta iznad gornje granice normale bila je jednaka onoj uz placebo, ali manja od one opažene u skupinama koje su kao usporedni lijek primale metformin ili sulfonilureju.
If you experience this symptom for the first time, talk to your doctor as soon as possible.
Ako prvi put osjetite ovaj simptom, čim prije razgovarajte Vašim liječnikom.
Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone.
KaplanMeierovom analizom pokazalo se da je vrijeme do prestanka odgovora na terapiju u bolesnika liječenih gliklazidom kraće nego kod liječenja pioglitazonom.
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months.
U placebo kontroliranom ispitivanju, bolesnici s neodgovarajućom kontrolom glikemije usprkos tromjesečnog razdoblja optimizacije inzulina bili su randomizacijom raspodijeljeni u skupinu koja je primala pioglitazon odnosno skupinu koja je primala placebo tijekom 12 mjeseci.
In comparator groups addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.
U skupinama koje su primale usporedni lijek, dodavanje sulfonilureje metforminu rezultiralo je prosječnim povećanjem tjelesne težine za 1,3 kg, a dodavanje metformina sulfonilureji smanjenjem tjelesne težine za 1,0 kg.
The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations.
Odluku o nastavku liječenja pioglitazonom treba donijeti na temelju kliničke procjene ovisno o laboratorijskim nalazima.
If you stop taking Pioglitazone Teva
Ako prestanete uzimati Pioglitazon Teva
Part of the treatment of diabetes is dietary control.
Dijeta s kontroliranim unosom kalorija dio je liječenja šećerne bolesti.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and preexisting major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
U PROactive ispitivanju kardiovaskularnih ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i postojećom teškom makrovaskularnom bolešću bilo je randomizacijom raspodijeljeno u skupinu koja je primala pioglitazon i onu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju u trajanju do 3,5 godine.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
usporednim kontroliranim ispitivanjima pioglitazona opažene su slične promjene u bolesnika liječenih metforminom (relativno smanjenje hemoglobina za 3-4% i hematokrita za 3,6-4,1%) i u manjoj mjeri u bolesnika liječenih sulfonilurejom i inzulinom (relativno smanjenje hemoglobina za 1-2% i hematokrita za 1-3,2%).
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator.
U PROactive ispitivanju u trajanju od 3,5 godine, 44/870 (5,1%) bolesnica liječenih pioglitazonom doživjelo je prijelom u usporedbi s 23/905 (2,5%; %) bolesnica liječenih usporednim lijekom.
Frequency of adverse reactions of pioglitazone by treatment regimen
Učestalost nuspojava pioglitazona prema režimu liječenja
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
Povećana incidencija prijeloma kostiju u žena opažena je u analizi objedinjenih podataka o prijelomima kostiju kao nuspojava u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima na više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih usporednim lijekom u trajanju do najviše 3,5 godine.
1 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported.
Opis odabranih nuspojava 1Nakon stavljanja lijeka u promet postoje izvještaji o reakcijama preosjetljivosti kod bolesnika liječenih pioglitazonom.
If you stop using Pioglitazone Teva, your blood sugar may go up.
Pioglitazon Teva, šećer u krvi Vam se može povisiti.
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
6 U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2-3 kg tijekom jedne godine.
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
4 Provedena je analiza objedinjenih podataka o prijelomima kostiju kao nuspojavama u randomiziranim, usporednim lijekom kontroliranim, dvostruko slijepim kliničkim ispitivanjima u više od 8100 bolesnika u skupinama liječenima pioglitazonom i 7400 bolesnika u skupinama liječenima usporednim lijekom u trajanju do 3,5 godine.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
U razdoblju nakon stavljanja lijeka u promet zabilježeni su slučajevi novonastalog ili pogoršanja već postojećeg dijabetičkog makularnog edema sa smanjivanjem oštrine vida uz tiazolidindione, uključujući pioglitazon.
Pioglitazone Teva contains pioglitazone.
Pioglitazon Teva sadrži pioglitazon.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Pioglitazone Teva and insulin experienced the development of heart failure.
U nekih bolesnika koji su dugo imali šećernu bolest tipa 2 i srčanu bolest ili su preboljeli moždani udar, a liječili su se lijekom Pioglitazon Teva i inzulinom došlo je do zatajenja srca.
- The active substance is pioglitazone.
- Djelatna tvar je pioglitazon.
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator.
U PROactive ispitivanju kardiovaskularnog rizika u trajanju od 3,5 godine, 44/870 (5,1%; 1,0 prijelom na 100 bolesnik-godina) bolesnica liječenih pioglitazonom doživjelo je prijelom u usporedbi s 23/905 (2,5%; 0,5 prijeloma na 100 bolesnik-godina) bolesnica liječenih usporednim lijekom.
If you forget to take Pioglitazone Teva
Ako ste zaboravili uzeti Pioglitazon Teva
Musculoskeletal and connective tissue disorders fracture bone4
Poremećaji mišićno-koštanog sustava i vezivnog tkiva prijelom kosti4
What you need to know before you take Pioglitazone Teva Do not take Pioglitazone Teva
Što morate znati prije nego počnete uzimati Pioglitazon Teva
There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8).
Nakon stavljanja lijeka u promet zabilježeni su rijetki slučajevi poremećaja hepatocelularne funkcije (vidjeti dio 4.8).
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite
često (mogu se javiti do 1 od 10 osoba) - glavobolja - omaglica - bol u zglobovima - impotencija - križobolja - nedostatak zraka - manje sniženje broja crvenih krvnih stanica - nadutost manje često (mogu se javiti do 1 od 100 osoba)
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution.
(relativno smanjenje za 4%) i hematokrita (relativno smanjenje za 4,1%), sukladno hemodiluciji.
Your weight should be checked at regular intervals; if your weight increases, inform your doctor.
Ako Vam se tjelesna težina poveća, obavijestite o tome
There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
Hiperplazija mokraćnog mjehura nije opažena u pasa i majmuna liječenih pioglitazonom u trajanju do 12 mjeseci.
Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking pioglitazone in combination with insulin.
Lokalizirano oteknuće (edemi) također su vrlo često (mogu se javiti u više od 1 od 10 osoba) nastajali u bolesnika koji su uzimali pioglitazon u kombinaciji s inzulinom.
Pioglitazone Teva 30 mg tablets EU/1/12/757/011-020
Pioglitazon Teva 30 mg tablete EU/1/12/757/011-020
Pioglitazone Teva 15 mg tablets EU/1/12/757/001-010
Pioglitazon Teva 15 mg tablete EU/1/12/757/001-010
It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes.
Stoga se u bolesnika liječenih pioglitazonom preporučuje povremeno određivati jetrene enzime.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih nejasnoća ili pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys.
U toksikološkim ispitivanjima nakon ponavljanja doziranja u miševa, štakora, pasa i majmuna dosljedno su primijećeni povećanje volumena plazme hemodilucijom, anemija i reverzibilna ekscentrična hipertrofija srca.
Pioglitazone Teva 45 mg tablets EU/1/12/757/021-030
Pioglitazon Teva 45 mg tablete EU/1/12/757/021-030
Pioglitazone Teva 15 mg tablets Pioglitazone Teva 30 mg tablets Pioglitazone Teva 45 mg tablets
Pioglitazon Teva 15 mg tablete Pioglitazon Teva 30 mg tablete Pioglitazon Teva 45 mg tablete
General disorders and administration site conditions oedema5
Opći poremećaji i reakcije na mjestu primjene edem5
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking pioglitazone.
Karcinom mokraćnog mjehura manje je često (mogu se javiti do 1 od 100 osoba) nastao u bolesnika koji uzimaju pioglitazon.
How to take Pioglitazone Teva
Kako uzimati Pioglitazon Teva
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).
Zabilježeno je da istovremena primjena pioglitazona s gemfibrozilom (inhibitor citokroma P450 2C8) povećava, a s rifampicinom (induktor citokroma P450 2C8) snižava koncentracije pioglitazona u plazmi (vidjeti dio 4.5).
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.
Zatajenje srca uz primjenu pioglitazona zabilježeno je nakon stavljanja lijeka u promet, i bilo je češće kad se pioglitazon primjenjivao u kombinaciji s inzulinom ili u bolesnika sa zatajenjem srca u anamnezi.
No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).
Nije bilo primijećeno povećanje stopa prijeloma u muškaraca liječenih pioglitazonom (1,3%) u odnosu na usporedni lijek (1,5%).
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Tablični prikaz nuspojava Nuspojave koje su bile zabilježene češće (> 0,5%) nego uz placebo ili kao izolirani slučaj u bolesnika koji su primali pioglitazon u dvostruko slijepim ispitivanjima navedene su niže prema MedDRA
31-546, Krakow Poland
Teva Operations Poland Sp z.o.o. ul. Mogilska 80. 31-546, Krakow Poljska
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%).
Viša stopa prijeloma bila je primijećena u žena koje su uzimale pioglitazon (2,6%) u odnosu na usporedni lijek (1,7%).
How to store Pioglitazone Teva
Kako čuvati Pioglitazon Teva
Carmellose calcium Hydroxypropylcellulose Magnesium stearate
6.1 Popis pomoćnih tvari manitol karmelozakalcij hidroksipropilceluloza magnezijev stearat
Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Teva.
Liječnik će tražiti da za vrijeme liječenja lijekom Pioglitazon Teva povremeno napravite krvne pretrage, da bi se provjerilo radi li Vaša jetra normalno.
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon
Poremećaji živčanog sustava hipoestezija glavobolja manje često omaglica nesanica manje često manje često manje često manje često manje često
Pioglitazone
Nuspojava
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).
Nije bilo primijećeno povećanje stopa prijeloma u muškaraca liječenih pioglitazonom (1,7%) u odnosu na one liječene usporednim lijekom (2,1%).
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.
Nakon stavljanja lijeka u promet zabilježeni su slučajevi zatajenja srca kad se pioglitazon primjenjivao u kombinaciji s inzulinom i u bolesnika sa zatajenjem srca u anamnezi.
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
Ako razvijete znakove zatajenja srca kao što su neuobičajeni nedostatak zraka, brzo povećanje tjelesne težine ili lokalizirana nateknuća (edemi), čim prije obavijestite o tome svog liječnika.
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone.
U bolesnika, naročito u žena koje uzimaju pioglitazon primijećen je povećan broj prijeloma kostiju.
Teva Pharmaceutical Works Private Limited Company Pallagi út 13
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Teva Pharmaceutical Works Private Limited Company Pallagi út 13
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva.
Za vrijeme liječenja lijekom Pioglitazon Teva obično možete nastaviti uzimati druge lijekove.
not known (frequency cannot be estimated from the available data) - increase in liver enzymes - allergic reactions
- povišenje vrijednosti jetrenih enzima - alergijske reakcije
Cardiac disorders heart failure3
Srčani poremećaji zatajenje srca3
- Pioglitazone Teva 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side.
- Pioglitazon Teva 45 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘45' na jednoj strani i ‘TEVA' na drugoj.
- Pioglitazone Teva 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side.
- Pioglitazon Teva 30 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘30' na jednoj strani i ‘TEVA' na drugoj.
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070
Österreich ratiopharm Arzneimittel Vertriebs-GmbH
Read the package leaflet before use.
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitajte Uputu o lijeku.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva.
Kad uzimate Pioglitazon Teva možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
Teva UK Ltd Brampton Road, Hampden Park, Eastbourne,
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Ujedinjeno Kraljevstvo
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon
Infekcije gornjih dišnih puteva bronhitis sinusitis manje često manje često manje često manje često manje često